Cited 0 times in
First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.